Clinical trials
catalyst calendar across sponsors →Studies where ORKA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 8 tracked-famous managers (VIKING GLOBAL INVESTORS LP, CITADEL ADVISORS LLC, Holocene Advisors, LP, Schonfeld Strategic Advisors LLC, MILLENNIUM MANAGEMENT LLC, +3 more) · FINRA short interest 8.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 18 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Open-Label Extension Study of ORKA-001 in Participants With Plaque PsoriasisNCT07449702Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: ORKA-001 | Plaque Psoriasis | 240 | May 2030 | ≤ 1,381 d | 2026-08-05 |
| Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07474792Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16Randomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: ORKA-002 · Other: Placebo | Plaque Psoriasis | 160 | Oct 2027 | ≤ 438 d | 2026-08-10 |
| Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07290569Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16Randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: ORKA-001 · Other: Placebo | Plaque Psoriasis | 160 | Jun 2027 | ≤ 315 d | 2026-08-17 |
| ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single DoseNCT06944379Incidence of Treatment-emergent Adverse EventsRandomized · Double-masked · Other | Phase 1 | Active, not recruiting | Drug: ORKA-002 · Other: Placebo | Healthy Volunteers | 24 | Jan 2027 | ≤ 165 d | 2025-09-26 |
| ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque PsoriasisNCT07090330Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16Randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: ORKA-001 Induction Dose, ORKA-001 Maintenance Dose · Other: Placebo | Plaque Psoriasis | 80 | 2026-03-25actual | — | 2026-07-01 |
| ORKA-001 in Healthy VolunteersNCT06698939Number and frequency of Treatment-Emergent Adverse Events [Safety and Tolerability]Randomized · Double-masked · Other | Phase 1 | Completed | Drug: ORKA-001 · Other: Placebo | Healthy Volunteers | 24 | 2026-03-13actual | — | 2026-04-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19